Global opioid induced constipation drugs market was valued at USD 1,933.2Mn in 2016 and is expected to reach USD 2,779.2Mn by 2022, with the market growing at a CAGR of 4.6% during the forecast period of 2016-2022.
Browse Full Report of Opioid Induced Constipation Drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016–2022 at http://www.credenceresearch.com/report/opioid-induced-constipation-oic-drugs-market
The OIC drugs market is dominated by over the counter prescription with 65.87% market share in 2014. The OTC drugs market will continue to dominate the market growing at the highest CAGR of 9.9% during the forecast period of 2016-2022.
Rising number of OIC sufferers is largely down to overall population increase and the continual use of opioids in the treatment of chronic non- cancer pain. Use of opioids is directly associated with frequently dose-limiting constipation that seriously impacts on patients quality of life. Considering the cause of constipation includes inadequate fluid intake, excessive dietary intake, irregular time for paving bowel movements increased OIC sufferes.
The global OIC drugs market is expanding across the region of the North America, Europe, Latin America, South East Asia and rest of the world. The North America is become the leading market for the OIC drugs and is expected to contribute USD 1167.3Mn in 2022 with the highest CAGR of 5.6% during the forecast period of 2016-2022. The OIC drugs market will grow frequently in the U.S. and five major European countries including France, Germany, Italy, Spain and U.K. was valued at US$ 67 in 2016 and is expected to grow more than US$652 by 2022.
Methylnaltrexone bromide, lubiprostone and naloxegol are the three drugs currently indicated for OIC treatment. Among these, methylnaltrexone bromide holds the largest market size and is expected to progress with a CAGR of 2.9% during the forecast period. Relistor from Salix Pharmaceuticals is indicated for treatment of OIC in patients with advanced illness receiving palliative care, particularly when standard laxative therapy proves insufficient. Lubiprostone under the brandname Amitiza is indicated for treating OIC, where it major indication is for chronic idiopathic constipation (CIC). Lubiprostone is expected that the segment will take over the market share of methylnaltrexone bromide. Additionally, naloxegol is expected to grow at highest CAGR over the forecast period. The drug is under testing for various patient types such as pregnant women and patients less than 17 years of age. Thus, future approvals are expected to lead the market.
However the majority of sales of OIC drugs will come from the U.S. which represents approximately 86% of the market by the end of the forecast period. In the U.S. OIC drugs are commonly prescribed class of medication for chronic pain; almost 50% of the U.S. population has suffering from on or other type of constipation.
Persistent constipation may lead to serious medical squeal including bowel obstruction and faecal impaction; increase in number of oral medications that are specifically designed to elevated use of prescribed drugs and medical services will grow the OIC drugs market. The leading players of OIC drugs market are Pfizer, AIKO biotechnology, Cubist Pharmaceuticals, Salix Pharmaceuticals, Takeda Pharmaceuticals limited and others.